Latest Forum Topics /
IX Biopharma
Last:0.355
+0.01
|
 Post Reply
|
|
iX Biopharma
|
|||||
|
Ww9696
Member |
21-Sep-2020 08:48
|
||||
|
x 0
x 0 Alert Admin |
Is It today. Dont disappoint again |
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
21-Sep-2020 08:37
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma gets Israel patent for drug delivery technologyhttp://www.businesstimes.com.sg/companies-markets/ix-biopharma-gets-israel-patent-for-drug-delivery-technology |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
guards80
Supreme |
21-Sep-2020 08:20
|
||||
|
x 0
x 0 Alert Admin |
Many good news coming 😁
|
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
21-Sep-2020 08:19
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma secures Israel patent for WaferiXhttp://www.theedgesingapore.com/news/company-news/ix-biopharma-secures-israel-patent-waferix |
||||
| Useful To Me Not Useful To Me | |||||
|
hmmhmm
Elite |
21-Sep-2020 08:16
|
||||
|
x 0
x 0 Alert Admin |
Hmm......hope XX wont made use of this opportunity for unloading.... | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SmallSmall
Supreme |
21-Sep-2020 07:53
|
||||
|
x 0
x 0 Alert Admin |
RELEASE iX Biopharma secures Israel patent for WaferiXTM drug delivery technology The US patent over WaferiXTM has also been issued by the United States Patent and Trademark Office WaferiXTM is now protected in 30 countries across 5 continents Singapore, 21 September 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo or &ldquo the Company&rdquo , and together with its subsidiaries, &ldquo the Group&rdquo ) is pleased to announce that it has been granted a patent in Israel (Patent no. 238104) for its WaferiXTM drug delivery technology. The patent will expire on 11 October 2033 and will provide key intellectual property protection for the Company' s WaferiXTM delivery technology platform in Israel. Further, iX Biopharma wishes to update that following its announcement on 9 June 2020 that it had received a notice of allowance from the United States Patent and Trademark Office for WaferiXTM(U.S. Patent Application No 13/504,309), the patent has now been issued as Patent no. 10,744,086. The patent will expire on 26 October 2030. WaferiXTM is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. Produced via the Group&rsquo s proprietary freeze-drying technique, the porous and amorphous WaferiXTM matrix holding the active molecules is designed to collapse quickly within the sublingual space before being transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action. In addition, the technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect. With Israel&rsquo s grant of patent, iX Biopharma&rsquo s intellectual property rights for its sublingual wafer technology is now secured in 5 continents and all key markets Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, and Indonesia, countries in including the United States, China, the European Union and others. |
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
20-Sep-2020 12:48
|
||||
|
x 0
x 0 Alert Admin |
IX BIOPHARMA: Blazing New Trails in Healthcare http://www.nextinsight.net/story-archive-mainmenu-60/943-2020/13775-ix-biopharma-blazing-new-trails-in-healthcare |
||||
| Useful To Me Not Useful To Me | |||||
|
look@bright
Elite |
19-Sep-2020 15:18
|
||||
|
x 0
x 0 Alert Admin |
The biggest losers are retailers who follow and bought above 30c before the announcement not the placement investors. They should blame themselves for being cheapskate!
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
guards80
Supreme |
19-Sep-2020 15:07
|
||||
|
x 0
x 0 Alert Admin |
http://www.businesstimes.com.sg/companies-markets/at-the-cutting-edge-of-biotechnology
|
||||
| Useful To Me Not Useful To Me | |||||
|
StevenKan
Master |
18-Sep-2020 13:36
|
||||
|
x 0
x 0 Alert Admin |
Those private investors who took the placement should go bang Dr Janakan Krishnarajah' s door. Ask him for explanation.... how the management manage the Company' s stock??? ahahahaha
|
||||
| Useful To Me Not Useful To Me | |||||
|
StevenKan
Master |
18-Sep-2020 13:31
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma: Blazing New Trails in HealthcareDr Janakan Krishnarajah has never shied away from thinking &ndash or dreaming &ndash big. In fact, setting bold targets is par for the course with him.&ldquo Be aware of self-imposed limitations,&rdquo said the Chief Medical Officer and Chief Operating Officer of SGX-listed specialty pharmaceutical company iX Biopharma Ltd. &ldquo You only have one life &ndash pursue it with your whole heart, and live without regrets.&rdquo For the last 20 years, Krishnarajah, a Bachelor of Medicine and Bachelor of Surgery with Honours graduate from the University of Western Australia, has relentlessly followed his passion. A Fellow of the Royal Australasian College of Physicians, he is a specialist in the fields of Clinical Pharmacology and Internal Medicine. &ldquo Internal medicine deals with a broad and complex range of issues &ndash you get to develop expertise in the diagnosis and treatment of chronic illnesses &ndash there&rsquo s quite a bit of detective work involved,&rdquo he said. &ldquo Clinical Pharmacology focuses on drugs and their optimal use to treat disease. If not used correctly, they can cause the patient more harm than good.&rdquo Krishnarajah feels privileged to be able to make a positive impact on the lives of others. &ldquo By producing safe and effective medicines in the drug development process, we help improve the health of thousands. It&rsquo s also intellectually challenging and satisfying to come up with solutions for patients and fulfill unmet clinical needs.&rdquo Between 2013 and 2016, the 42-year-old held the position of CEO and Medical Director at Linear Clinical Research Ltd, a leading Australian early phase clinical trials facility. There, he developed extensive experience in Phases I-IV clinical trials, and acted as Principal or Co-Investigator in more than a hundred Phase I-II clinical trials. In April 2016, Krishnarajah joined iX Biopharma as CMO, and was subsequently promoted to COO three years later. &ldquo Previously, although I designed and ran the clinical trials, I never got to see the final stage, as companies would take the successful products to register them in their respective countries. Now at iX, I&rsquo m involved in the end-to-end process of drug development &ndash from discovery to registration, manufacturing and marketing,&rdquo he said. &ldquo It&rsquo s deeply satisfying to see all that design and planning come to fruition through the patients who use these products.&rdquo Cutting-Edge Listed on SGX Catalist in 2015, iX Biopharma has established itself as a specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development and manufacturing, to sales and marketing, with facilities in Australia. It focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions, using its cutting-edge, patented sublingual delivery technology, WaferiX. The Group&rsquo s nutraceuticals division, Entity Health Ltd, is also engaged in the development and commercialisation of nutraceutical products that address specific health conditions and needs. Looking ahead, iX Biopharma&rsquo s twin growth engines will be its pharmaceutical and nutraceutical divisions, underpinned by its WaferiX delivery technology, said Krishnarajah. WaferiX is a multiple drug carrier platform that allows pharmacologically active compounds to be administered sublingually, or under the tongue. Produced via its proprietary freeze-drying technique, the porous and amorphous matrix holding the drug molecules is designed to collapse under the tongue within a minute, thus delivering the active compounds safely, conveniently and rapidly into the blood stream. This technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect. The Group&rsquo s intellectual property rights for this technology has been secured in key markets such as the United States, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, Indonesia, as well as countries in the European Union. The Group has also filed corresponding patent applications in other jurisdictions that will allow it to seek similar patent protection in key markets throughout the world. This delivery technology is also applied across iX Biopharma&rsquo s pipeline of products that include Wafermine, the world&rsquo s first ketamine product delivered sublingually, and Wafesil, a sublingual sildenafil drug, which has obtained approval and registration in Australia, for the treatment of male erectile dysfunction. It has also developed a cannabidiol (CBD) drug &ndash Xativa &ndash using WaferiX, making it the world&rsquo s first freeze-dried, sublingual medicinal cannabis wafer. Crown Jewel Currently, the jewel in iX Biopharma&rsquo s crown is Wafermine. The group is in the process of out-licensing the product. The Group has made good progress so far, having concluded its End-of-Phase II meeting with the US Food and Drug Administration (FDA) last December, with both parties reaching an agreement on key aspects of the pivotal Phase III clinical trial program to support approval of Wafermine to treat moderate to severe acute pain. &ldquo We plan to pursue the monetising of Wafermine via partnerships with suitable pharmaceutical, biotech or other partners to advance the clinical development programme beyond Phase II,&rdquo Krishnarajah said. &ldquo Typically, to find a suitable partner to undertake Phase III, it&rsquo s an involved process, and COVID-19 has not helped. Things are progressing well, however, and we&rsquo re working through a number of interesting candidates,&rdquo he added. An out-licensing agreement usually involves a host of payments &ndash upfront payment upon contract signing, as well as payments on the achievement of milestones in the Phase III clinical trial, and as the product progresses on its commercialisation path. Meanwhile, Xativa, which the Group is evaluating for the treatment of anxiety, tremor and inflammatory conditions, also offers huge potential. &ldquo CBD alternatives in the market today suffer from poor oral bioavailability,&rdquo Krishnarajah said. &ldquo Xativa was created to address the shortcomings of alternative delivery methods like smoking and vapourising, or other oral preparations, such as oil extracts.&rdquo &ldquo Sublingual delivery is fast-becoming the most preferred method of consuming CBD, allowing a user to maximise the benefits of its active compounds,&rdquo he added. Last December, iX Biopharma announced its wholly owned subsidiary iX Syrinx was granted a cannabis manufacture licence from the Office of Drug Control in Australia. Together with import and export licences that were already in hand, this latest licence opens up significant avenues for the Group to participate in the global medicinal cannabis business. The legal cannabis industry has seen explosive growth over the last two years. The size of the global cannabis market was estimated at US$13.8 billion in 2018, and is projected to reach US$66.3 billion by end-2025, expanding at a compound annual growth rate (CAGR) of about 24% over the seven years. In its most significant milestone to-date, iX Biopharma has inked its maiden agreement with medicinal cannabis enterprise Cannatrek to supply Xativa to the Australian market. Following its roll-out in Australia at the end of April, Xativa&rsquo s initial production runs totalling 1,700 boxes have been fully sold. &ldquo We&rsquo ve seen tremendous enthusiasm from doctors and patients &ndash they&rsquo ve acknowledged that Xativa is different from other products as it offers fixed unit dosing, improved speed and level of absorption, as well as predictability of effect,&rdquo Krishnarajah added. &ldquo Xativa is also expected to be a superior alternative for certain population segments, such as senior citizens and the young, as it&rsquo s easy to use and doesn&rsquo t require swallowing capsules or ingesting oils, which may be harder to tolerate.&rdquo Gold Standard The third prong of iX Biopharma&rsquo s strategy involves its nutraceutical arm, Entity Health. To address high-growth categories like beauty, anti-ageing and lifestyle needs, the Group aims to roll out two to three new Entity products annually. Entity&rsquo s nutraceuticals are manufactured in the Group&rsquo s Therapeutic Goods Administration- (TGA) approved and Good Manufacturing Practice- (GMP) compliant facility located in Victoria, Australia, and sold in more than 250 pharmacies and health food stores across Sydney, Melbourne and Perth. Its products have also been available online in Singapore since December 2017. Entity Health is currently tapping on e-commerce sales channels in China following the launch of online stores on JD.com and Alibaba&rsquo s Tmall Global in April. These two stores provide market access to more than 85% of the total business-to-consumer (B2C) e-commerce market in China. &ldquo China is a high-priority market and big growth driver for us,&rdquo Krishnarajah noted. &ldquo Australian-made health supplements are regarded by Chinese consumers as the gold standard of products due to the country&rsquo s reputation for safety and quality. We expect this market to grow from strength to strength.&rdquo Its Entity Health products and the licensing of its pharmaceutical drug Wafesil to Yiling Pharmaceutical for the China market in April this year have placed iX Biopharma &ldquo on the map&rdquo . &ldquo We&rsquo re in talks with a couple of Chinese pharmaceutical companies about our WaferiX platform as a result,&rdquo he added. While the overall outlook remains bright, the Group is grappling with production capacity constraints. &ldquo COVID-19 lockdowns have hampered our production capacity upgrades by delaying equipment installation, due to restrictions for overseas-based engineers to come onsite to commission the equipment,&rdquo Krishnarajah said. &ldquo These upgrades would have boosted our manufacturing capability by six-fold.&rdquo The Group is exploring alternative options, such as getting local engineering contractors to commission its new equipment. &ldquo We&rsquo re optimistic we can boost production capacity soon, and this in turn will give us the confidence to pursue the numerous deals out there,&rdquo he added. And when he is not strategising for the Group&rsquo s operations, Krishnarajah can be found with his three sons, aged 10 months, five and seven. Family time usually involves playing ball, other sports, and a board game or two. &ldquo My kids are growing up so quickly &ndash it&rsquo s important to spend whatever time I have with them,&rdquo he smiled. &ldquo I want them to have a spirit of positivity,&rdquo he added. More importantly, they must cultivate resilience and an indomitable spirit. &ldquo I always tell my two older boys &ndash dream big, and never ever, ever give up!&rdquo https://www.sgx.com/research-education/market-dialogues/20200918-ix-biopharma-blazing-new-trails-healthcare?utm_medium=sgxinvest& utm_source=Telegram& utm_campaign=alwayson& utm_content=MU |
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
18-Sep-2020 12:14
|
||||
|
x 0
x 0 Alert Admin |
Price stable at 220. Think wont go down any more. Placement share holdwr compliant liao | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
seanpent
Supreme |
18-Sep-2020 10:10
|
||||
|
x 0
x 0 Alert Admin |
23 is just round the corner .....
|
||||
| Useful To Me Not Useful To Me | |||||
|
seanpent
Supreme |
18-Sep-2020 09:52
|
||||
|
x 0
x 0 Alert Admin |
Seems very well maintained
|
||||
| Useful To Me Not Useful To Me | |||||
|
churnw
Elite |
17-Sep-2020 21:30
|
||||
|
x 0
x 0 Alert Admin |
Last chance to get at this price ....
Even placement at 0.23 |
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
17-Sep-2020 16:25
|
||||
|
x 0
x 0 Alert Admin |
Need some time stay above 230. Today market sentiment no good. Let see tmr.
|
||||
| Useful To Me Not Useful To Me | |||||
|
seanpent
Supreme |
17-Sep-2020 14:42
|
||||
|
x 0
x 0 Alert Admin |
and hope it will move above placement price anytime soon
|
||||
| Useful To Me Not Useful To Me | |||||
|
seanpent
Supreme |
17-Sep-2020 14:37
|
||||
|
x 0
x 0 Alert Admin |
guess the norm feeling la hor ..... no one wants it that way .....
|
||||
| Useful To Me Not Useful To Me | |||||
|
guards80
Supreme |
17-Sep-2020 14:26
|
||||
|
x 0
x 0 Alert Admin |
actually they want placement at 30cents but they want discount... now below discount sure compliant haha
|
||||
| Useful To Me Not Useful To Me | |||||
|
seanpent
Supreme |
17-Sep-2020 14:19
|
||||
|
x 0
x 0 Alert Admin |
OIC ....
|
||||
| Useful To Me Not Useful To Me | |||||